Valsts: Austrālija
Valoda: angļu
Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)
Mitozantrone hydrochloride
Baxter Healthcare Pty Ltd
Medicine Registered
ONKOTRONE (mitozantrone) Consumer Medicine Information ONKOTRONE CMI 030505 Page 1 of 5 Baxter ONKOTRONE _Mitozantrone _ CONSUMER MEDICINE INFORMATION_ _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about ONKOTRONE. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking ONKOTRONE against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT ONKOTRONE IS USED FOR ONKOTRONE is used to treat various types of cancer. These include breast cancer, non- Hodgkin’s lymphoma (a cancer of the lymph glands), and leukaemia. ONKOTRONE belongs to a group of medicines called antineoplastic or cytotoxic medicines. You may also hear of these being called chemotherapy medicines. ONKOTRONE works by stopping cancer cells from growing and multiplying. Your doctor may have prescribed ONKOTRONE for another reason. Ask your doctor if you have any questions about why ONKOTRONE has been prescribed for you. ONKOTRONE may be used in combination with other medicines to treat cancer. ONKOTRONE is not addictive. This medicine is available only with a doctor’s prescription. BEFORE YOU ARE GIVEN ONKOTRONE _WHEN YOU MUST NOT BE GIVEN IT _ DO NOT HAVE ONKOTRONE IF YOU HAVE AN ALLERGY TO ONKOTRONE OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET. Symptoms of an allergic reaction to ONKOTRONE may include: shortness of breath, wheezing, difficulty breathing or a tight feeling in Izlasiet visu dokumentu
1 ONKOTRONE (mitozantrone hydrochloride) APPROVED PRODUCT INFORMATION NAME OF DRUG Mitozantrone (as hydrochloride) DESCRIPTION Mitozantrone hydrochloride is a synthetic anthracenedione. The chemical name is 1,4-dihydroxy-5,8-bis-[2-(2-hydroxyethylamino)-ethylamino]-9,10- anthraquinone dihydrochloride, and the chemical structure is as follows: The molecular formula is C 22 H 28 N 4 O 6 .2HCl, and the molecular weight is 517.4. The CAS No. is 70476-82-3. Mitozantrone hydrochloride is a hygroscopic dark blue solid. ONKOTRONE Concentrated Injection is a clear, dark blue liquid with a pH of 3.0-4.5. One mL of the solution for injection contains 2.328 mg mitozantrone hydrochloride (equivalent to 2 mg mitozantrone), with sodium chloride, sodium acetate, acetic acid-glacial and water for injection as excipients. PHARMACOLOGY Mitozantrone hydrochloride is a cytostatic agent that has shown substantial anti-tumour activity in the treatment of a variety of tumours. It is a DNA- reactive agent, but the precise mechanism of the tumour destroying effect has not yet been completely elucidated. Mitozantrone acts both on proliferating and non-proliferating cells. It is a cell cycle (phase) non-specific substance. The main toxic effects of mitozantrone in animals at doses within the human therapeutic range are reversible myelosuppression (predominantly leucopenia, with anaemia and thrombocytopenia being less severe) and lymphocytic depletion of the lymphoid organs. In continuous daily dosage 2 schedules, gastrointestinal haemorrhage and congestion were observed, but these were not seen in intermittent schedules as used clinically. Studies in dogs using mitozantrone in combination with other antineoplastic agents indicated that additive myelosuppression might be expected from c Izlasiet visu dokumentu